We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
(+14%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-22.17%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$13.1M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$10.3M |
| 3 |
Opko Health
OPK
|
+$7.29M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$6.72M |
| 5 |
Gilead Sciences
GILD
|
+$6.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MannKind Corp
MNKD
|
+$22.4M |
| 2 |
Arbutus Biopharma
ABUS
|
+$9.33M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$5.53M |
| 4 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$4.82M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$4.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 10.45% |
| 2 | Energy | 0.15% |
| 3 | Communication Services | 0% |
| 4 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
26
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
| $15.9M | 0.89% |
+3,497
| New | +$167K |
|
|
ITMN
27
PUT
DELISTED
INTERMUNE INC
ITMN
| $15.7M | 0.88% |
4,681
+2,843
| +155% | +$63.3K |
|
|
PCYC
28
PUT
DELISTED
PHARMACYCLICS INC
PCYC
| $15.3M | 0.86% |
1,529
+1,456
| +1,995% | +$189K |
|
29
PUT
AbbVie
ABBV
$465B
| $15.3M | 0.86% |
+2,979
| New | +$151K |
|
|
PCYC
30
CALL
DELISTED
PHARMACYCLICS INC
PCYC
| $15M | 0.84% |
+1,500
| New | +$195K |
|
31
PUT
Amgen
AMGN
$212B
| $14M | 0.79% |
+1,138
| New | +$138K |
|
32
CALL
Pfizer
PFE
$144B
| $13.8M | 0.77% |
+4,533
| New | +$135K |
|
|
CLVS
33
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $13.4M | 0.75% |
1,931
+1,897
| +5,579% | +$139K |
|
34
CALL
Thermo Fisher Scientific
TMO
$214B
| $13.2M | 0.74% |
+1,100
| New | +$131K |
|
|
35
Tenax Therapeutics
TENX
$419M
| $11.8M | 0.66% |
+66
| New | +$13.1M |
|
36
CALL
Merck
MRK
$326B
| $11.4M | 0.64% |
2,113
-11,335
| -84% | -$587K |
|
37
Acadia Pharmaceuticals
ACAD
$4.45B
| $11.3M | 0.63% |
463,146
-93,867
| -17% | -$2.37M |
|
|
GEVA
38
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $11M | 0.62% |
+1,331
| New | +$123K |
|
|
39
Gilead Sciences
GILD
$167B
| $11M | 0.62% |
155,073
+77,073
| +99% | +$6.04M |
|
|
AUXL
40
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $10.8M | 0.61% |
+3,983
| New | +$106K |
|
|
AGN
41
PUT
DELISTED
Allergan Inc
AGN
| $10.7M | 0.6% |
863
-753
| -47% | -$91.7K |
|
42
PUT
iShares Russell 2000 ETF
IWM
$80.4B
| $10.4M | 0.58% |
+890
| New | +$103K |
|
43
CALL
Eli Lilly
LLY
$1.09T
| $10.1M | 0.57% |
+1,719
| New | +$95.9K |
|
44
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $9.76M | 0.55% |
4,060
-3,413
| -46% | -$87K |
|
45
PUT
Ionis Pharmaceuticals
IONS
$9.14B
| $8.98M | 0.5% |
2,078
-258
| -11% | -$12.5K |
|
|
KERX
46
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $8.93M | 0.5% |
5,238
+4,646
| +785% | +$70.1K |
|
|
BPTH
47
DELISTED
Bio-Path Holdings Inc
BPTH
| $8.78M | 0.49% |
+828
| New | +$10.3M |
|
|
48
PUT
MannKind Corp
MNKD
$1.21B
| $8.49M | 0.48% |
4,222
+886
| +27% | +$25.2K |
|
|
49
Sarepta Therapeutics
SRPT
$1.63B
| $8.46M | 0.47% |
352,100
-155,600
| -31% | -$3.97M |
|
|
50
Opko Health
OPK
$1.23B
| $7.75M | 0.43% |
+831,237
| New | +$7.29M |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2014 Portfolio in Review
As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.
Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.
- Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
- Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
- Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
- Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
- Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
- Sabby Management opened 107 new positions and closed 92 in Q1 2014.
- Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.
Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.